Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 2:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sugar test Clear all
Recruiting Phase 3 Interventional

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

NCT05624996
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions
Carboplatin, Cisplatin, Computed Tomography, Durvalumab, Etoposide, Image Guided Radiation Therapy, Nab-paclitaxel, Osimertinib, Paclitaxel, Pemetrexed, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Procedure · Biological + 2 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
476
States / cities
Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 357 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 13, 2026, 2:30 PM EDT
Terminated Phase 3 Interventional Results available

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction

NCT03037580
View directory record Official record
Conditions
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions
Oral treprostinil, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Sep 13, 2026, 2:30 PM EDT
Active, not recruiting Phase 2 Interventional

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

NCT05826964
View directory record Official record
Conditions
Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions
AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI, mTOR inhibitor + SERD, mTOR inhibitor + Selective estrogen receptor modulator, PI3K inhibitor + SERD, PI3K inhibitor + AI, Chemotherapy, Oral SERD, PARPi, AKT inhibitor, Step 3 Arm 2
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 13, 2026, 2:30 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

NCT05710328
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
Interventions
Chemotherapy, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Surgical Procedure
Drug · Procedure · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
97
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 81 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 13, 2026, 2:30 PM EDT
Terminated Not applicable Interventional Results available

Continuous Glucose Monitoring in Critically Ill

NCT00707434
View directory record Official record
Conditions
Diabetes
Interventions
Guardian® blood-sugar monitoring device
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
6
States / cities
Dallas, Texas • Galveston, Texas • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Sep 13, 2026, 2:30 PM EDT
Terminated No phase listed Observational

GDM Post Partum Screening

NCT03946631
View directory record Official record
Conditions
Diabetes, Gestational Diabetes, Diabetes Mellitus, Type 2
Interventions
2 hour glucose tolerance test using 75g glucose drink
Diagnostic Test
Lead sponsor
Pediatrix
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Sep 13, 2026, 2:30 PM EDT
Completed Phase 3 Interventional

At Home Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAs) System and Run-to-Run Adaptation

NCT02705053
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
CGM and Insulin Pump, Closed-Loop Control System
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Santa Barbara, California • Rochester, Minnesota • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Sep 13, 2026, 2:30 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

NCT07016399
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Breast Biopsy Procedure, Carboplatin, Cyclophosphamide, Darolutamide, Doxorubicin, Epirubicin, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Surgical Procedure, Ultrasound Imaging
Procedure · Drug · Biological
Lead sponsor
Vandana Abramson
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 13, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography

NCT02455453
View directory record Official record
Conditions
Breast Cancer
Interventions
18F-FFNP, CTI/Siemens Biograph 40 PET/CT Scanner, Estradiol, 18F-FDG
Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 13, 2026, 2:30 PM EDT
Recruiting Phase 2 Interventional

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

NCT07046078
View directory record Official record
Conditions
Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Echocardiography Test, Fludarabine, Idarubicin, Multigated Acquisition Scan, Peripheral Blood Stem Cell, Questionnaire Administration, Recombinant Granulocyte Colony-Stimulating Factor, Total-Body Irradiation
Procedure · Drug · Biological + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 13, 2026, 2:30 PM EDT
Enrolling by invitation Not applicable Interventional

Using Remote Monitoring to Address Health Disparities in Type 2 Diabetes

NCT06517576
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Blood glucose monitor with Digital Platform and Health Coaching, Continuous glucose monitor, Usual Care
Device · Other
Lead sponsor
Lawndale Christian Health Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 13, 2026, 2:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Two Novel Hydration Beverage Formulas on Rehydration in Adults

NCT06063655
View directory record Official record
Conditions
Dehydration
Interventions
Control: Water, Liquid IV hydration multiplier, Liquid IV sugar-free hydration multiplier
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
18 Years to 49 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 13, 2026, 2:30 PM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

NCT04190550
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Interventions
Cytarabine, Idarubicin Hydrochloride, Navtemadlin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 13, 2026, 2:30 PM EDT
Completed No phase listed Observational

Use of CoG by Patients With Diabetes Mellitus

NCT03840161
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
non-invasive tissue glucose prediction
Device
Lead sponsor
Sciema UG
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 13, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes

NCT00971789
View directory record Official record
Conditions
Cowden's Disease, Hamartoma Syndrome, Multiple
Interventions
fludeoxyglucose F 18, sirolimus, Clinical Videography
Radiation · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2015 · Synced Sep 13, 2026, 2:30 PM EDT
Completed No phase listed Observational

Development of Predictive Biomarkers

NCT03423862
View directory record Official record
Conditions
Type1diabetes
Interventions
Mixed Meal Tolerance Test
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
5 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 13, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients

NCT00948090
View directory record Official record
Conditions
Lymphoma
Interventions
IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
37
States / cities
Birmingham, Alabama • Tucson, Arizona • Berkeley, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Sep 13, 2026, 2:30 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

NCT02911142
View directory record Official record
Conditions
Primary Effusion Lymphoma, B-Cell Neoplasm
Interventions
Lenalidomide, Rituximab, Prednisone, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, CT of neck, chest, abdomen and pelvis, 18FDG-PET scan, MRI Brain, Bone marrow biopsy, EKG, Echocardiogram, Ultrasound, Bronchoscopy, Endoscopy, CXR: PA/lat/decub
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 13, 2026, 2:30 PM EDT
Not yet recruiting Phase 1 Interventional

Impact of Sweeteners on the Addictive Threshold of Nicotine

NCT07771725
View directory record Official record
Conditions
Smoking ( Cigarette)
Interventions
Nicotine 0.05 mg/pulse and 0.1 mg/pulse, Saline Placebo (0.5mL injection), sucralose, Sugar syrup (Placebo)
Drug · Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
21 Years to 59 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 13, 2026, 2:30 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Complex Effects of Dietary Manipulation on Metabolic Function, Inflammation and Health

NCT02706262
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Metabolically abnormal obese - Mediterranean diet, Metabolically abnormal obese - Low carbohydrate ketogenic diet, Metabolically abnormal obese - Plant-based, very-low-fat diet, Annual Follow-up Visits
Other · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 13, 2026, 2:30 PM EDT
Active, not recruiting Phase 2 Interventional

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

NCT03269669
View directory record Official record
Conditions
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
Interventions
Bendamustine Hydrochloride, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Lenalidomide, Multigated Acquisition Scan, Obinutuzumab, Positron Emission Tomography, Prednisone, Umbralisib, Vincristine Sulfate
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
429
States / cities
Anchorage, Alaska • Tucson, Arizona • Anaheim, California + 292 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 13, 2026, 2:30 PM EDT
Recruiting Not applicable Interventional

MOMs Chat and Care Study

NCT06335381
View directory record Official record
Conditions
Severe Maternal Morbidity
Interventions
Maternal Health Education Resources, Prenatal Telehealth Visits, Postpartum Telehealth Visits, Home Blood Pressure Monitor, Fitbit
Other · Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 13, 2026, 2:30 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Precision Nutrition and Metabolic Function

NCT04131166
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Mediterranean diet, Low-carbohydrate, ketogenic diet, Low-fat diet, Annual follow-up testing for 5 years
Behavioral · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 13, 2026, 2:30 PM EDT
Active, not recruiting Phase 1 Interventional

Vagal Stimulation in POTS

NCT03124355
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
placebo sugar pill, Pyridostigmine Pill, Galantamine Pill, Vagal stimulation, Sham vagal stimulation
Drug · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 13, 2026, 2:30 PM EDT